Drotrecogin alfa (activated) in adults with septic shock.

BACKGROUND There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock. METHODS In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infection, systemic inflammation, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 μg per kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was death from any cause 28 days after randomization. RESULTS At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92 to 1.28; P=0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to 1.19; P=0.56). Among patients with severe protein C deficiency at baseline, 98 of 342 (28.7%) in the DrotAA group had died at 28 days, as compared with 102 of 331 (30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 0.74 to 1.17; P=0.54). Similarly, rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death. Serious bleeding during the treatment period occurred in 10 patients in the DrotAA group and 8 in the placebo group (P=0.81). CONCLUSIONS DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).

[1]  G. Salanti,et al.  Human recombinant activated protein C for severe sepsis (Review) , 2009 .

[2]  G. Bernard,et al.  Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis , 2003, Critical care.

[3]  Mark D. Williams,et al.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial , 2007, The Lancet.

[4]  D. Semmler,et al.  Risk stratification in emergency surgical patients: is the APACHE II score a reliable marker of physiological impairment? , 2001, Archives of surgery.

[5]  Sowmya R Rao,et al.  Survival Methods , 2007, Circulation.

[6]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[7]  J.,et al.  The New England Journal of Medicine , 2012 .

[8]  Gary Garber,et al.  The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000) , 2001 .

[9]  Jon Cohen,et al.  A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis* , 2010, Critical care medicine.

[10]  P. Barie,et al.  Unblinding plan of PROWESS-SHOCK trial , 2011, Intensive Care Medicine.

[11]  G. Bernard,et al.  Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome , 2006, Critical care.

[12]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[13]  Arise.  The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. , 2007, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[14]  P. Barie,et al.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock , 2008, Intensive Care Medicine.

[15]  R. Maharaj.  Vasopressors and the search for the optimal trial design. , 2011, Contemporary clinical trials.

[16]  Richard Beale,et al.  The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis , 2010, Intensive Care Medicine.

[17]  Massimo Antonelli,et al.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). , 2007, American journal of respiratory and critical care medicine.

[18]  Brian H Cuthbertson,et al.  Hydrocortisone therapy for patients with septic shock. , 2008, The New England journal of medicine.

[19]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[20]  J. Helterbrand,et al.  Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis , 2003, Critical care medicine.

[21]  S. Opal,et al.  Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis* , 2010, Critical care medicine.

[22]  J. Escarce,et al.  Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score. , 1990, JAMA.

[23]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[24]  B. Gårdlund.  Activated protein C (Xigris®) treatment in sepsis: a drug in trouble , 2006, Acta anaesthesiologica Scandinavica.

[25]  P. Barie,et al.  Statistical analysis plan of PROWESS SHOCK study , 2010, Intensive Care Medicine.

[26]  Amber E Barnato,et al.  Use of intensive care at the end of life in the United States: An epidemiologic study* , 2004, Critical care medicine.

[27]  G. Bernard,et al.  Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial* , 2003, Critical care medicine.

[28]  J. Bakker,et al.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial , 2003, Intensive Care Medicine.

[29]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[30]  S. Lowry,et al.  Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. , 2004, Surgical infections.

[31]  A. H. Dinsmore,et al.  New England , 1894, Letters from America.

[32]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[33]  Soumitra R. Eachempati,et al.  Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. , 2011, Surgical infections.

[34]  G. Bernard,et al.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis * , 2004, Critical care medicine.

[35]  C. Perry,et al.  Drotrecogin Alfa (Activated) , 2012, Drugs.

[36]  D. Nelson,et al.  Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.

[37]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[38]  V. Pettilä,et al.  Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation 1 , 2004, Journal of thrombosis and haemostasis : JTH.

[39]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.